Mixed trend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Dec 26 · inside the Ichimoku cloud · RSI 0 (oversold) · MACD above its signal · at its 52-week low
None of the 29 investors followed here reported a position in RASP in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RASP trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -87.5 | −87.5% |
| 2024 | 3.9 | -3.8 | 0.0 | 124.7 | -2.3 | -90.5 | 150.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −48.1% |
| 2023 | 65.6 | 28.7 | 15.4 | -62.0 | 0.0 | 336.8 | -9.6 | -11.1 | 0.0 | -61.5 | 0.0 | 0.0 | +26.2% |
| 2022 | -19.4 | -7.4 | 0.0 | -99.6 | 0.0 | 11000.0 | 0.0 | 9.9 | 0.0 | -78.7 | 134.6 | 0.0 | −81.8% |
| 2021 | 20.0 | 18.3 | -29.6 | 0.0 | 60.0 | 68.8 | -77.8 | 0.0 | 100.0 | -8.5 | -52.6 | 28.8 | −33.0% |
| 2020 | -60.0 | 0.0 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 53.3 | 63.0 | 2.7 | -2.6 | -33.3 | −66.7% |
| 2019 | -48.1 | 0.0 | -46.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −72.2% |
| 2018 | -23.3 | -13.0 | 0.0 | -5.0 | -2.6 | -40.5 | -9.1 | -45.0 | -12.7 | -48.1 | 68.7 | 28.6 | −82.0% |
| 2017 | 13.5 | 0.0 | 3.8 | -31.2 | 158.7 | 3.1 | 12.5 | -11.1 | 0.0 | -37.5 | 0.0 | 20.0 | +62.2% |
| 2016 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 127.5 | 90.5 | -7.5 | +300.8% |
| 2015 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -25.0 | 0.0 | 0.0 | 0.0 | −25.0% |
No insider transactions reported for RASP.
No analyst coverage for this instrument.
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, develops therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma in the United States. It is developing RASP-201, an orally dosed selective reversible inhibitor of lysine specific demethylase (LSD1), which is a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301. The company was formerly known as Rasna Therapeutics, Inc. and changed its name to Actavia Life Sciences, Inc. in October 2023. Actavia Life Sciences, Inc. was founded in 2013 and is based in New York, New York.
No recent headlines.